Amphastar Pharma (AMPH) Misses Q4 EPS by 3c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.88, $0.03 worse than the analyst estimate of $0.91. Revenue for the quarter came in at $178.1 million versus the consensus estimate of $173.35 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital